読み込み中
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
通常取引
$1.595
+$0.055 · +3.57%
日中の時刻はETです。市場データは遅延する場合があります。
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
日中レンジ
現在 $1.595
52週レンジ
現在 $1.595
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
58
適正価値
センチメント
69
強気
リスク
64
高リスク
モメンタム
49
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
日中レンジ
現在 $1.595
52週レンジ
現在 $1.595
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | 25万 USD | — | — |
| 粗利益 | — | — | 25万 USD | — | — |
| 研究開発 | 1019.2万 USD | 906.3万 USD | 689.3万 USD | 654.7万 USD | 243万 USD |
| 販売・一般管理 | 786.4万 USD | 579.6万 USD | 620.2万 USD | 876.4万 USD | 930.7万 USD |
| 営業費用 | 1805.6万 USD | 1485.9万 USD | 1332万 USD | 1572.1万 USD | 4185.4万 USD |
| 受取利息 | — | — | — | 1.3万 USD | — |
| 支払利息 | 1万 USD | 1.2万 USD | 1.5万 USD | 1.3万 USD | 239.8万 USD |
| 減価償却費と償却費 | 3000 USD | 3000 USD | 4000 USD | 3000 USD | 2000 USD |
| 営業利益 | −1805.6万 USD | −1485.9万 USD | −1307万 USD | −1572.1万 USD | −4185.4万 USD |
| 純利益 | −1678.1万 USD | −1443.8万 USD | −1230万 USD | −1426万 USD | −2661.6万 USD |
会社概要が更新されました 2026年10月12日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$4.50
上昇余地（182.13%）AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
